Entries by BioSpace

, , ,

Gilead’s Hep B Trial Failure Will Inspire M&A Activity, Say Analysts

After yesterday’s announcement of disappointing results for Gilead Sciences, Inc. (GILD) and GlobeImmune, Inc. (GBIM)’s Phase II clinical trial of hepatitis drug GS-4774, analysts are speculating on whether Gilead will respond by buying its way into another market. The trial of GS-4774 for hepatitis B had a primary endpoint of reducing hepatitis B surface antigen […]

,

A Good Night’s Sleep Helps Fix Deeply Rooted Attitudes, Northwestern University Study

A Good Night’s Sleep Helps Modify Deeply Rooted Attitudes Long-held social biases can be reduced during sleep, a new report suggests. It adds further support to recent research that has shown that memories can be selectively reactivated and strengthened during slumber. Scientists have known that sleep boosts memory formation by resuscitating faint neuron activity shaped […]

, , ,

With A $1.2 Billion Hammer, The Federal Trade Commission Closes Loophole To Prevent Generic Drugs

This morning, the U.S. Federal Trade Commission drew blood: Teva Pharmaceuticals will pay $1.2 billion to reimburse insurers, drug wholesalers, and pharmacies who paid full price for the Provigil, produced by Cephalon, a company Teva bought in 2011, because Cephalon had paid generic drugmakers to delay launching cheaper versions of the blockbuster drug. Hey, check […]

,

The Most Exciting Companies in Biotech

May 28, 2015By Aja Frost for BioSpace.com Many employees don’t have the luxury of choosing exciting jobs. They pick their position or workplace based on more quotidian concerns: paying their bills, getting a stable job and receiving good benefits. But the awesome part about working in biotech? You can get all those perks and have […]

, , , ,

Editas Medicine, Juno Therapeutics (JUNO) Hammer Out $727 Million CAR T R&D Deal

White-hot CAR-T darling Juno Therapeutics (JUNO) is at it again, announcing Thursday that is has inked a massive $727 million deal with Editas Medicine , the gene editing company, for a partnership that will forge three research programs marrying Editas’ technologies, including CRISPR/Cas9, to Juno’s CAR and TCR technologies. Under the terms of the deal, […]

,

Novartis AG to Show Off New Data on 21 Meds and 11 Investigational Compounds at Major Conferences

Novartis Presents New Data On 21 Medicines And 11 Investigational Compounds At ASCO And EHA   Overall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell lung cancer (NSCLC) and first Phase II data for Tafinlar and Mekinist in […]

,

Probiotics May Help Ease Allergies, Vanderbilt University Study Shows

Study Shows Probiotics May Help Ease Allergies Using probiotics may help alleviate the symptoms of allergic rhinitis (AR), also known as seasonal or perennial allergies, according to a Vanderbilt study that reviewed 23 previous trials. The results were published in April in the online version of the journal International Forum of Allergy & Rhinology. “When […]